Blog
RSS FeedPosted by Michael Wonder on 06 Apr 2020
India has cut off half the supply of a potential coronavirus treatment touted by Trump
6 April 2020 - Nearly half the supply of hydroxychloroquine to the U.S. comes from makers in India, a flow ...
Posted by Michael Wonder on 06 Apr 2020
Amendments to the new restrictions on prescribing hydroxychloroquine for COVID-19
6 April 2020 - On 24 March 2020, new restrictions came into effect limiting the health practitioners who could initiate ...
Posted by Michael Wonder on 06 Apr 2020
Trump pushed health officials to make anti-malaria drugs available as coronavirus treatment: report
4 April 2020 - President Trump pushed health health officials to make anti-malaria drugs available to treat the coronavirus although ...
Posted by Michael Wonder on 06 Apr 2020
Rybelsus (oral semaglutide) approved for the treatment of adults with type 2 diabetes in the EU
4 April 2020 - Novo Nordisk today announced that the European Commission (EC) has granted marketing authorisation for Rybelsus (oral ...
Posted by Michael Wonder on 05 Apr 2020
Canada takes cautious approach to unapproved COVID-19 drugs, as others prescribe wide use
5 April 2020 - 'One perspective is "We’re in a time of desperation and let’s throw anything we can at it." ...
Posted by Michael Wonder on 05 Apr 2020
Why FDA’s issuance of EUAs are not ‘approvals’ and why that matters
3 April 2020 - You may have read that some drugs are now “approved” to treat COVID-19, or as the ...
Posted by Michael Wonder on 04 Apr 2020
Australian scientists discover head lice drug kills coronavirus in lab
4 April 2020 - Melbourne researchers say an anti-parasitic drug commonly used to combat head lice has been found to ...
Posted by Michael Wonder on 04 Apr 2020
IVERIC bio announces fast track designation from U.S. FDA for Zimura for the treatment of geographic atrophy secondary to dry age-related macular degeneration
3 April 2020 - IVERIC bio announced today that the U.S. FDA has granted fast track designation to Zimura (avacincaptad ...
Posted by Michael Wonder on 04 Apr 2020
Swiss Government expands powers to force firms to make supplies to fight COVID-19
3 April 2020 - The Swiss government on Friday boosted its powers to order companies to raise production of critical ...
Posted by Michael Wonder on 03 Apr 2020
U.S. FDA approves Reblozyl (luspatercept-aamt), the first and only erythroid maturation agent, to treat anaemia in adults with lower-risk myelodysplastic syndromes
3 April 2020 - The FDA approval marks the second indication for Reblozyl and the first new treatment option in ...
Posted by Michael Wonder on 03 Apr 2020
EMA provides recommendations on compassionate use of remdesivir for COVID-19
3 April 2020 - During an extraordinary virtual meeting held on 2 April 2020, EMA’s CHMP gave recommendations on how ...
Posted by Michael Wonder on 03 Apr 2020
International regulators discuss available knowledge supporting COVID-19 medicine development
3 April 2020 - On 2 April, regulators from around the world joined the second workshop on COVID-19 organised by ...
Posted by Michael Wonder on 03 Apr 2020
Zealand Pharma submits new drug application to the U.S. FDA for the dasiglucagon HypoPal Rescue Pen for treatment of severe hypoglycemia
31 March 2020 - The dasiglucagon HypoPal Rescue Pen new drug application represents a major milestone in Zealand Pharma’s efforts to ...
Posted by Michael Wonder on 02 Apr 2020
Biosimilars could disappear if the Supreme Court overturns the ACA
1 April 2020 - With the sense of urgency rightly focused on slowing or stopping the spread of COVID-19, it ...
Posted by Michael Wonder on 02 Apr 2020
Pfizer receives European approval for oncology biosimilar Ruxience (rituximab)
2 April 2020 - Pfizer today announced that the European Commission has approved Ruxience (rituximab), a monoclonal antibody and biosimilar to ...